Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19

Résumé en anglais

Introduction : Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread worldwide in 2020 leading the World Health Organization to declare a pandemic. Patients with thoracic cancers have been reported at higher risk to develop severe disease, and die from COVID-19. In this setting, clinical practice recommendations for the management of patients were published. We report here how these guidelines were implemented in a routine practice setting.

Methods : We retrospectively collected the characteristics, treatment regimen and modification, as well as COVID-19 status and death for all patients with thoracic malignancies scheduled for an appointment at Institute Curie from March 23rd to April 17th 2020.

Results : A total of 339 patients were included. Treatment strategy was modified for a total of 110 (32%) patients because of COVID-19; these modifications were in accordance with guidelines for 92% of patients. The majority of dose modifications were related to immune checkpoint inhibitors, for which switch to flat dosing every 4 to 6 weeks was made. A total of 5 (1.5%) patients were diagnosed with COVID-19 disease, 1 of whom died from disease complication.

Conclusion : Our study provides a unique insight in the decision making for patients with thoracic malignancies in the setting of COVID-19 outbreak, showing how guidelines were implemented in the clinic, and what may be optimized in the clinical practice of thoracic oncology in the future.